The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Diane Brady: Leadership Next is powered by the folks at Deloitte who, like me, are exploring the changing roles of business ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors ...

Lilly to Develop Two Targets Identified and Validated Using ’ AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of ...

An update from Eli Lilly & Co ( (LLY) ) is now available.